DEVA Holding Çerkezköy-I Manufacturing Facility has an enclosed area of 43,000 m2 established on an area of 52,000 m2 in the Çerkezköy Organized Industrial Zone, at a distance of approximately 110 km from Istanbul.

The facility is made up of modern buildings where liquids/semi-solids and solids, cephalosporin, penicillin, hormone products, inhaled products, sterile liquid ampoules and vials and soft gel capsules are manufactured.

While a total of 201 million units were manufactured in the facility in 2023, the total output in 2024 reached 196 million units.

Liquids/Semi-Solids and Solids Manufacturing Unit

In the Liquids/Semi-Solids Manufacturing Unit, medicines in the form of syrup, drops and spray, cream and gel, suppositories and ovules are manufactured with stateofthe-art technology.

In this unit, while a total of 40.9 million units were manufactured in 2023, the total output in 2024 reached 42.2 million units, including 31.8 million bottles of syrups, drops, and sprays, as well as 10.4 million units of ointments, creams, gels, suppositories, and ovules.

In the Liquid Manufacturing Unit, unit-based production in 2024 increased by 3% compared to 2023, resulting in an additional 1.3 million units being manufactured.

 

 

In the Solids Manufacturing Unit, medicines in the form of tablets/film tablets, capsules, and powders for suspension are manufactured with state-of-the-art technology.

In this unit, while a total of 72.8 million units were manufactured in 2023, a total of 72.5 million units were manufactured in 2024, including 69.1 million units of tablets/capsules, soft gel capsules, and 3.4 million units of suspensions.

 

 

Cephalosporin Manufacturing Unit (Beta-lactam I)

In the Cephalosporin Manufacturing Unit, while a total of 29.7 million units were manufactured in 2023, a total of 26.2 million units were manufactured in 2024, consisting of 19.9 million units of sterile powder for injectable vials, 1.5 million units of oral suspension, and 4.8 million units of film-coated tablets and capsules.

 

 

Penicillin Manufacturing Unit (Beta-lactam II)

In the Penicillin Manufacturing Unit, while a total of 29.7 million units were manufactured in 2023, a total of 27 million units were manufactured in 2024, consisting of 5.1 million units of sterile powder for injectable vials, 7.6 million units of oral suspension, and 14.3 million units of film-coated tablets.

Hormone Products Manufacturing Unit

While a total of 24.5 million units were manufactured in the Hormonal Products Manufacturing Unit in 2023, the total output in 2024 reached 22.9 million units, including 4.1 million units of creams/pomade, 3.6 million units of solid tablets and film-coated tablets, and 15.2 million units of sterile ampoules, vials, and drops.

Inhaled Products Manufacturing Unit

While a total of 2.6 million units were manufactured in the Inhalation Products Manufacturing Unit in 2023, the total output in 2024 reached 3.5 million units.

In the Inhaler Manufacturing Unit, production in 2024 increased by 36% compared to 2023.

 

Sterile Liquid Ampoules, Vials and Soft Gel Capsules Manufacturing Unit

While a total of 1.5 million units were manufactured in the Sterile Liquid Ampoule and Vial Manufacturing Unit in 2023, the total output in 2024 reached 1.8 million units.

In 2024, production increased by 20% compared to 2023.